The drugmaker incurred debt when it acquired Shire, a U.K.-based drugmaker, in 2019, and the sale of its nonprescription drug division is intended to relieve some of that debt.
Takeda will focus its management resources on developing prescription drugs, the company told the Nikkei Asian Review. It plans to sell a total of $10 billion in assets.
Read the full article here.
More articles on pharmacy:
FDA halts approval of blood plasma as COVID-19 treatment
J&J to acquire Momenta Pharma for $6.5B
US sues Teva for alleged MS drug kickback scheme
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.